The key role of calmodulin in KRAS-driven adenocarcinomas

Molecular Cancer Research

Volumn 13, Issue 9, 2015, Pages 1265-1273

  Nussinov, Ruth ^a   Muratcioglu, Serena ^b   Tsai, Chung Jung ^a   Jang, Hyunbum ^a   Gursoy, Attila ^b   Keskin, Ozlem ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b KOÇ UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

A RAF KINASE; CALMODULIN; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; CALCIUM; ISOPROTEIN; KRAS PROTEIN, HUMAN; PROTEIN P21;

ADENOCARCINOMA; CELL GROWTH; CELL PROLIFERATION; COLORECTAL CANCER; GENE MUTATION; HUMAN; LUNG CANCER; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; GENETICS; METABOLISM; MUTATION; NEOPLASM;

ADENOCARCINOMA; ANIMALS; CALCIUM; CALMODULIN; HUMANS; MUTATION; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION;

EID: 84941808747     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-15-0165     Document Type: Review

References (131)

1. Nussinov R, Tsai CJ, Mattos C. 'Pathway drug cocktail': targeting Ras signaling based on structural pathways. TrendsMol Med 2013;19:695-704.
2. Cox AD, der CJ. Ras history: the saga continues. Small GTPases 2010;1:2-27.
3. Calvisi DF, Frau M, Tomasi ML, Feo F, Pascale RM. Deregulation of signalling pathways in prognostic subtypes of hepatocellular carcinoma: novel insights from interspecies comparison. Biochim Biophys Acta 2012;1826:215-37.
4. Nussinov R, Ma B, Tsai CJ. A broad view of scaffolding suggests that scaffolding proteins can actively control regulation and signaling of multienzyme complexes through allostery. Biochim Biophys Acta 2013;1834:820-9.
5. Xu Y, Li N, Xiang R, Sun P. Emerging roles of the p38MAPKand PI3K/AKT/mTOR pathways in oncogene-induced senescence. Trends Biochem Sci 2014;39:268-76.
6. Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev 1998;8:49-54.
7. Khosravi-Far R, Campbell S, Rossman KL, der CJ. Increasing complexity of Ras signal transduction: involvement of Rho family proteins. Adv Cancer Res 1998;72:57-107.
8. Roy S, Luetterforst R, Harding A, Apolloni A, Etheridge M, Stang E, et al. Dominant-negative caveolin inhibits H-Ras function by disrupting cholesterol-rich plasma membrane domains. Nat Cell Biol 1999;1:98-105.
9. Yan J, Roy S, Apolloni A, Lane A, Hancock JF. Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J Biol Chem 1998;273:24052-6.
10. Johnson L, Greenbaum D, Cichowski K, Mercer K, Murphy E, Schmitt E, et al. K-ras is an essential gene in the mousewith partial functional overlap with N-ras. Genes Dev 1997;11:2468-81.
11. Esteban LM, Vicario-Abejon C, Fernandez-Salguero P, Fernandez-Medarde A, Swaminathan N, Yienger K, et al. Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol Cell Biol 2001;21:1444-52.
12. Choy E, Chiu VK, Silletti J, Feoktistov M, Morimoto T, Michaelson D, et al. Endomembrane trafficking of ras: the CAAX motif targets proteins to the ER and Golgi. Cell 1999;98:69-80.
13. Hancock JF, Paterson H, Marshall CJ. A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell 1990;63:133-9.
14. Jackson JH, Li JW, Buss JE, der CJ, Cochrane CG. Polylysine domain of Kras 4B protein is crucial formalignant transformation. Proc Natl Acad Sci U S A 1994;91:12730-4.
15. Barbacid M. ras genes. Annu Rev Biochem 1987;56:779-827.
16. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
17. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004;91:355-8.
18. Castellano E, Santos E. Functional specificity of ras isoforms: so similar but so different. Genes Cancer 2011;2:216-31.
19. Castellano E, Downward J. RAS interaction with PI3K: More than just another effector pathway. Genes Cancer 2011;2:261-74.
20. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011;11:761-74.
21. Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res 2012;72:2457-67.
22. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med 2014;371:1039-49.
23. Bryant KL, Mancias JD, Kimmelman AC, der CJ. KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci 2014;39:91-100.
24. Guerra C, Schuhmacher AJ, Canamero M, Grippo PJ, Verdaguer L, Perez-Gallego L, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adultmice. Cancer Cell 2007;11:291-302.
25. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437-50.
26. Morris JPt, Wang SC, Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 2010;10:683-95.
27. Pinho AV, Rooman I, Reichert M, De Medts N, Bouwens L, Rustgi AK, et al. Adult pancreatic acinar cells dedifferentiate to an embryonic progenitor phenotype with concomitant activation of a senescence programme that is present in chronic pancreatitis. Gut 2011;60:958-66.
28. Seidler B, Schmidt A, Mayr U, Nakhai H, Schmid RM, Schneider G, et al. A Cre-loxP-based mouse model for conditional somatic gene expression and knockdown in vivo by using avian retroviral vectors. Proc Natl Acad Sci U S A 2008;105:10137-42.
29. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
30. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
31. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
32. Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A, et al. Cosmic 2005. Br J Cancer 2006;94:318-22.
33. Hruban RH, Maitra A, Goggins M. Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol 2008;1:306-16.
34. Matthaios D, Zarogoulidis P, Balgouranidou I, Chatzaki E, Kakolyris S. Molecular pathogenesis of pancreatic cancer and clinical perspectives. Oncology 2011;81:259-72.
35. Canto MI, Hruban RH, Fishman EK, Kamel IR, Schulick R, Zhang Z, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 2012;142:796-804.
36. Feldmann G, Beaty R, Hruban RH, Maitra A. Molecular genetics of pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Surg 2007;14:224-32.
37. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-6.
38. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012;491:399-405.
39. Hidalgo M. New insights into pancreatic cancer biology. Ann Oncol 2012;23 Suppl 10:x135-8.
40. Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res 2012;18:4266-76.
41. Poruk KE, Firpo MA, Mulvihill SJ. Screening for pancreatic cancer. Adv Surg 2014;48:115-36.
42. Hustinx SR, Leoni LM, Yeo CJ, Brown PN, Goggins M, Kern SE, et al. Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion. Mod Pathol 2005;18:959-63.
43. Eser S, Schnieke A, Schneider G, Saur D. Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer 2014;111:817-22.
44. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012;149:656-70.
45. Collins MA, Bednar F, Zhang Y, Brisset JC, Galban S, Galban CJ, et al. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest 2012;122:639-53.
46. Collins MA, Brisset JC, Zhang Y, Bednar F, Pierre J, Heist KA, et al. Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. PLoS ONE 2012;7:e49707.
47. Lim KH, Baines AT, Fiordalisi JJ, Shipitsin M, Feig LA, Cox AD, et al. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell 2005;7:533-45.
48. Feldmann G, Mishra A, Hong SM, Bisht S, Strock CJ, Ball DW, et al. Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. Cancer Res 2010;70:4460-9.
49. Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM, et al. A central role for RAF-
50. Eser S, Reiff N, Messer M, Seidler B, Gottschalk K, Dobler M, et al. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell 2013;23:406-20.
51. Neel NF, Martin TD, Stratford JK, Zand TP, Reiner DJ, der CJ. The RalGEFRal effector signaling network: the road less traveled for anti-RAS drug discovery. Genes Cancer 2011;2:275-87.
52. Bodemann BO, White MA. Ral GTPases and cancer: linchpin support of the tumorigenic platform. Nat Rev Cancer 2008;8:133-40.
53. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas containmutant c-K-ras genes. Cell 1988;53:549-54.
54. Lim KH, O'Hayer K, Adam SJ, Kendall SD, Campbell PM, der CJ, et al. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. Curr Biol 2006;16:2385-94.
55. Vigil D, Martin TD, Williams F, Yeh JJ, Campbell SL, der CJ. Aberrant overexpression of the Rgl2 Ral small GTPase-specific guanine nucleotide exchange factor promotes pancreatic cancer growth through Ral-dependent and Ral-independent mechanisms. J Biol Chem 2010;285:34729-40.
56. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-13.
57. Blasco RB, Francoz S, Santamaria D, Canamero M, Dubus P, Charron J, et al. c-Raf, but not B-Raf, is essential for development of K-Ras oncogenedriven non-small cell lung carcinoma. Cancer Cell 2011;19:652-63.
58. Karreth FA, Frese KK, De Nicola GM, Baccarini M, Tuveson DA. C-Raf is required for the initiation of lung cancer by K-Ras (G12D). Cancer Discov 2011;1:128-36.
59. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008;14:1351-6.
60. Castellano E, Sheridan C, Thin MZ, Nye E, Spencer-Dene B, Diefenbacher ME, et al. Requirement for interaction of PI3-kinase p110alpha with RAS in lung tumor maintenance. Cancer Cell 2013;24:617-30.
61. Navas C, Hernandez-Porras I, Schuhmacher AJ, Sibilia M, Guerra C, Barbacid M. EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 2012;22:318-30.
62. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
63. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR. Nature 2012;483:100-3.
64. Klee CB, Vanaman TC. Calmodulin. Adv Protein Chem 1982;35:213-321.
65. Agell N, Aligue R, Alemany V, Castro A, Jaime M, Pujol MJ, et al. New nuclear functions for calmodulin. Cell Calcium 1998;23:115-21.
66. Cheung WY. Calmodulin plays a pivotal role in cellular regulation. Science 1980;207:19-27.
67. Bachs O, Agell N, Carafoli E. Calmodulin and calmodulin-binding proteins in the nucleus. Cell Calcium 1994;16:289-96.
68. Berchtold MW, Villalobo A. The many faces of calmodulin in cell proliferation, programmed cell death, autophagy, and cancer. Biochim Biophys Acta 2014;1843:398-435.
69. Villalonga P, Lopez-Alcala C, Bosch M, Chiloeches A, Rocamora N, Gil J, et al. Calmodulin binds to K-Ras, but not to H- or N-Ras, and modulates its downstream signaling. Mol Cell Biol 2001;21:7345-54.
70. Lopez-Alcala C, Alvarez-Moya B, Villalonga P, Calvo M, Bachs O, Agell N. Identification of essential interacting elements in K-Ras/calmodulin binding and its role in K-Ras localization. J Biol Chem 2008;283:10621-31.
71. Fivaz M, Meyer T. Reversible intracellular translocation of KRas but not HRas in hippocampal neurons regulated by Ca2+/calmodulin. J Cell Biol 2005;170:429-41.
72. Abraham SJ, Nolet RP, Calvert RJ, Anderson LM, Gaponenko V. The hypervariable region of K-Ras4B is responsible for its specific interactions with calmodulin. Biochemistry 2009;48:7575-83.
73. Liao J, Planchon SM, Wolfman JC, Wolfman A. Growth factor-dependent AKT activation and cell migration requires the function of c-K (B)-Ras versus other cellular ras isoforms. J Biol Chem 2006;281:29730-8.
74. Jang H, Abraham SJ, Chavan TS, Hitchinson B, Khavrutskii L, Tarasova NI, et al. Mechanisms of membrane binding of small GTPase K-Ras4B farnesylated hypervariable region. J Biol Chem 2015;290:9465-77.
75. Bosch M, Gil J, Bachs O, Agell N. Calmodulin inhibitor W13 induces sustained activation of ERK2 and expression of p21 (cip1). J Biol Chem 1998;273:22145-50.
76. De Luca A, Maiello MR, D'Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012;16 Suppl 2:S17-27.
77. Kahan C, Seuwen K, Meloche S, Pouyssegur J. Coordinate, biphasic activation of p44 mitogen-activated protein kinase and S6 kinase by growth factors in hamster fibroblasts. Evidence for thrombin-induced signals different from phosphoinositide turnover and adenylylcyclase inhibition. J Biol Chem 1992;267:13369-75.
78. Pumiglia KM, Decker SJ. Cell cycle arrest mediated by the MEK/mitogenactivated protein kinase pathway. Proc Natl Acad Sci U S A 1997;94:448-52.
79. Qui MS, Green SH. PC12 cell neuronal differentiation is associated with prolonged p21ras activity and consequent prolonged ERK activity. Neuron 1992;9:705-17.
80. Roovers K, Assoian RK. Integrating the MAP kinase signal into the G1 phase cell cycle machinery. BioEssays 2000;22:818-26.
81. Chen Y, Zhang YZ, Zhou ZG, Wang G, Yi ZN. Identification of differently expressed genes in human colorectal adenocarcinoma. World J Gastroenterol 2006;12:1025-32.
82. Liu GX, Sheng HF, Wu S. A study on the levels of calmodulin and DNA in human lung cancer cells. Br J Cancer 1996;73:899-901.
83. Barry S, Crnogorac-Jurcevic T. S100P (S100 calcium binding protein P). Atlas Genet Cytogenet Oncol Haematol 2009;13:429-31.
84. Lok T, Chen L, Lin F, Wang HL. Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma. Hum Pathol 2014;45:394-400.
85. Hu H, Zhang Q, Huang C, Shen Y, Chen X, Shi X, et al. Diagnostic value of S100P for pancreatic cancer: a meta-analysis. Tumour Biol 2014;35:9479-85.
86. Mori Y, Ohtsuka T, Kono H, Nagayoshi Y, Ideno N, Aso T, et al. A minimally invasive and simple screening test for detection of pancreatic ductal adenocarcinoma using biomarkers in duodenal juice. Pancreas 2013;42:187-92.
87. Heil A, Nazmi AR, Koltzscher M, Poeter M, Austermann J, Assard N, et al. S100P is a novel interaction partner and regulator of IQGAP1. J BiolChem 2011;286:7227-38.
88. Briggs MW, Sacks DB. IQGAP1 as signal integrator: Ca2+, calmodulin, Cdc42 and the cytoskeleton. FEBS Lett 2003;542:7-11.
89. Tekletsadik YK, Sonn R, Osman MA. A conserved role of IQGAP1 in regulating TOR complex 1. J Cell Sci 2012;125:2041-52.
90. Bauer I, Grozio A, Lasiglie D, Basile G, Sturla L, Magnone M, et al. The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses. J Biol Chem 2012;287:40924-37.
91. Genkinger JM, Wang M, Li R, Albanes D, Anderson KE, Bernstein L, et al. Dairy products and pancreatic cancer risk: a pooled analysis of 14 cohort studies. Ann Oncol 2014;25:1106-15.
92. Choi DL, Jang SJ, Cho S, Choi HE, Rim HK, Lee KT, et al. Inhibition of cellular proliferation and induction of apoptosis in human lung adenocarcinoma A549 cells by T-type calcium channel antagonist. Bioorg Med Chem Lett 2014;24:1565-70.
93. Ay AS, Benzerdjerb N, Sevestre H, Ahidouch A, Ouadid-Ahidouch H. Orai3 constitutes a native store-operated calcium entry that regulates non small cell lung adenocarcinoma cell proliferation. PLoS ONE 2013;8:e72889.
94. Dong Q, Zhang Y, Yang XH, Jing W, Zheng LQ, Liu YP, et al. Serum calcium level used as a prognostic predictor in patients with resectable pancreatic ductal adenocarcinoma. Clin Res Hepatol Gastroenterol 2014;38:639-48.
95. Joyal JL, Burks DJ, Pons S, Matter WF, Vlahos CJ, White MF, et al. Calmodulin activates phosphatidylinositol 3-kinase. J Biol Chem 1997;272:28183-6.
96. Rajakulendran T, Sahmi M, Lefrancois M, Sicheri F, Therrien M. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 2009;461:542-5.
97. Crews CM, Erikson RL. Extracellular signals and reversible protein phosphorylation: what to Mek of it all. Cell 1993;74:215-7.
98. Muratcioglu S, Tanmay SC, Freed BC, Jang H, Khavrutskii L, Freed RN, et al. GTP-dependent K-Ras dimerization. Structure 2015;23:1325-35.
99. Cho KJ, Kasai RS, Park JH, Chigurupati S, Heidorn SJ, Van Der Hoeven D, et al. Raf inhibitors target ras spatiotemporal dynamics. Curr Biol 2012;22:945-55.
100. Karbowniczek M, Robertson GP, Henske EP. Rheb inhibits C-raf activity and B-raf/C-raf heterodimerization. J Biol Chem 2006;281:25447-56.
101. Sidhu RS, Clough RR, Bhullar RP. Ca2+/calmodulin binds and dissociates K-RasB from membrane. Biochem Biophys Res Commun 2003;304:655-60.
102. Rodriguez-Viciana P, Sabatier C, McCormick F. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol Cell Biol 2004;24:4943-54.
103. Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 2012;1825:29-36.
104. Liao J, Wolfman JC, Wolfman A. K-ras regulates the steady-state expression of matrix metalloproteinase 2 in fibroblasts. J Biol Chem 2003;278:31871-8.
105. Aytuna AS, Gursoy A, Keskin O. Prediction of protein-protein interactions by combining structure and sequence conservation in protein interfaces. Bioinformatics 2005;21:2850-5.
106. Ogmen U, Keskin O, Aytuna AS, Nussinov R, Gursoy A. PRISM: protein interactions by structural matching. Nucleic Acids Res 2005;33:W331-6.
107. Tuncbag N, Gursoy A, Nussinov R, Keskin O. Predicting protein-protein interactions on a proteome scale by matching evolutionary and structural similarities at interfaces using PRISM. Nat Protoc 2011;6:1341-54.
108. Vadas O, Burke JE, Zhang X, Berndt A, Williams RL. Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Sci Signal 2011;4:re2.
109. Herrmann C, Martin GA, Wittinghofer A. Quantitative analysis of the complex between p21ras and the Ras-binding domain of the human Raf-1 protein kinase. J Biol Chem 1995;270:2901-5.
110. Sydor JR, Engelhard M, Wittinghofer A, Goody RS, Herrmann C. Transient kinetic studies on the interaction of Ras and the Ras-binding domain of c-Raf-1 reveal rapid equilibration of the complex. Biochemistry 1998;37:14292-9.
111. Herrmann C, Horn G, Spaargaren M, Wittinghofer A. Differential interaction of the ras family GTP-binding proteins H-Ras, Rap1A, and R-Ras with the putative effector molecules Raf kinase and Ral-guanine nucleotide exchange factor. J Biol Chem 1996;271:6794-800.
112. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 2001;70:535-602.
113. Nussinov R, Tsai CJ. The design of covalent allosteric drugs. Annu Rev Pharmacol Toxicol 2015;55:249-67.
114. Miled N, Yan Y, Hon WC, Perisic O, Zvelebil M, Inbar Y, et al. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 2007;317:239-42.
115. Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, Kinzler KW, et al. The structure of a human p110 alpha/p85 alpha complex elucidates the effects of oncogenic PI3K alpha mutations. Science 2007;318:1744-8.
116. Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110 alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A 2008;105:2652-7.
117. Geering B, Cutillas PR, Nock G, Gharbi SI, Vanhaesebroeck B. Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc Natl Acad Sci U S A 2007;104:7809-14.
118. Carpenter CL, Auger KR, Chanudhuri M, Yoakim M, Schaffhausen B, Shoelson S, et al. Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the sh2 domains of the 85-kda subunit. J Biol Chem 1993;268:9478-83.
119. Backer JM, Myers MG, Shoelson SE, Chin DJ, Sun XJ, Miralpeix M, et al. Phosphatidylinositol 30-kinase is activated by association with irs-1 during insulin stimulation. EMBO J 1992;11:3469-79.
120. Carson JD, Van Aller G, Lehr R, Sinnamon RH, Kirkpatrick RB, Auger KR, et al. Effects of oncogenic p110 alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. Biochem J 2008;409:519-24.
121. Mandelker D, Gabelli SB, Schmidt-Kittler O, Zhu JX, Cheong I, Huang CH, et al. A frequent kinase domain mutation that changes the interaction between PI3K alpha and the membrane. Proc Natl Acad Sci U S A 2009;106:16996-7001.
122. Kodaki T, Woscholski R, Hallberg B, Rodriguezviciana P, Downward L, Parker PJ. The activation of phosphatidylinositol 3-kinase by ras. Curr Biol 1994;4:798-806.
123. Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, Nicke B, et al. Binding of Ras to phosphoinositide 3-kinase p110 alpha is required for Ras-driven tumorigenesis in mice. Cell 2007;129:957-68.
124. Gabelli S, Echeverria I, Alexander M, Duong-Ly K, Chaves-Moreira D, Brower E, et al. Activation of PI3Ka by physiological effectors and by oncogenic mutations: structural and dynamic effects. Biophys Rev 2014;6:89-95.
125. Burke JE, Perisic O, Masson GR, Vadas O, Williams RL. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110 alpha (PIK3CA). Proc Natl Acad Sci U S A 2012;109:15259-64.
126. Zhao L, Vogt PK. Class IPI3K in oncogenic cellular transformation. Oncogene 2008;27:5486-96.
127. Yang HW, Shin M-G, Lee S, Kim J-R, Park WS, Cho K-H, et al. Cooperative activation of PI3K by Ras and Rho family small GTPases. Mol Cell 2012;47:281-90.
128. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, et al. Tumour biology - Senescence in premalignant tumours. Nature 2005;436:642-.
129. Nussinov R, Tsai CJ. Allostery in disease and in drug discovery. Cell 2013;153:293-305.
130. Nussinov R, Tsai CJ. Unraveling structural mechanisms of allosteric drug action. Trends Pharmacol Sci 2014;35:256-64.
131. Cukuroglu E, Gursoy A, Keskin O. HotRegion: a database of predicted hot spot clusters. Nucleic Acids Res 2012;40:D829-33.